Citations

Clear

4847 citation(s) found for "Tu, Eric".

Does vigorous exercise have a neuroprotective effect in Parkinson disease?
Ahlskog, J. Eric

Mayo Clinic

Neurology | July 18, 2011 | Volume: 77 | Issue: 3 | Pages: 288-294

10.1212/wnl.0b013e318225ab66 | PMID 21768599 Get It

Plasma Cell Myeloma and Related Neoplasms
Lorsbach, Robert B., Hsi, Eric D. , Doǧan, Ahmet , Fend, Falko

Mayo Clinic

American Journal of Clinical Pathology | July 14, 2011 | Volume: 136 | Issue: 2 | Pages: 168-182

10.1309/ajcpenj68ffbriyb | PMID 21757591 Get It

Abstract Session 1 of the 2009 Workshop of the Society for Hematopathology/European Association of Haematopathology, Cleveland, OH, focused on plasma cell neoplasms. This report summarizes the salient diagnostic, clinical, and genetic features of plasma cell myeloma (PCM) and related neoplasms. Based on the cases submitted to the workshop, we highlight common diagnostic issues and unusual manifestations of plasma cell neoplasms, such as t(11;14)+ PCM, plasma cell leukemia, and nonsecretory plasmacytoma, as well as plasmablastic transformation of PCM. Additional issues repeatedly raised at the workshop included the differential diagnosis of extramedullary dissemination of PCM vs primary extramedullary plasmacytoma and plasmablastic lymphoma; systemic plasma cell neoplasms in immunocompromised people; and Epstein-Barr virus–associated plasma cell neoplasms. Difficult cases with borderline features presented by submitters emphasized the necessity of integrating clinical, immunophenotypic, and genetic features for appropriate classification of these disorders.
Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients
Huang, R. Stephanie , Johnatty, Sharon E. , Gamazon, Eric R. , Im, Hae Kyung , Ziliak, Dana, Zhang, Wei , Kistner, Emily O., Chen, Peixian , Beesley, Jonathan, Mi, Shuangli , O’Donnell, Peter H. , Fraiman, Yarden S. , Das, Soma , Cox, Nancy J. , Lu, Yi , MacGregor, Stuart , Goode, Ellen L. , Vierkant, Robert A. , Høgdall, Estrid , Kjær, Susanne K. , Jensen, Allan , Moysich, Kirsten B., Grasela, Matthew, Odunsi, Kunle , Brown, Robert , Paul, Jim, Lambrechts, Diether , Despierre, Evelyn, Vergote, Ignace , Gross, Jenny , DeFazio, Anna , Chenevix‐Trench, Georgia , Dolan, M. Eileen , Lambrechts, Diether , Duan, Shiwei , Fridley, Brooke L. , Paul, Jim, Karlan, Beth Y. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Jensen, Allan , Vierkant, Robert A , Moysich, Kirsten , Brown, Robert , Lambrechts, Diether , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Huang, R Stephanie , Im, H K

Mayo Clinic

Clinical Cancer Research | June 25, 2011 | Volume: 17 | Issue: 16 | Pages: 5490-5500

10.1158/1078-0432.ccr-11-0724 | PMID 21705454 Get It

Abstract Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy. Experimental Design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (Pper-allele = 2 × 10−2), with a stronger effect in the subset of women with optimally debulked tumors (Pper-allele = 4 × 10−3). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (Pper-allele = 9 × 10−3). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts. Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect. Clin Cancer Res; 17(16); 5490–500. ©2011 AACR.
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G., Broadwater, Gloria , Bleiweiss, Ira J. , Edgerton, Susan M., Cowan, David P., Goldstein, Lori J. , Martino, Silvana, Henderson, I. Craig, Norton, Larry , Hudis, Clifford A. , Berry, Donald A. , Hayes, Daniel F. , B, for the Cancer and Leukemia Group, Ingle, James N. , Winer, Eric P. , Ellis, Matthew J. , B, for the Cancer and Leukemia Group, Norton, Larry

Mayo Clinic

Clinical Cancer Research | June 21, 2011 | Volume: 17 | Issue: 15 | Pages: 5170-5178

10.1158/1078-0432.ccr-11-0484 | PMID 21693655 Get It

Abstract Purpose: p53 as a prognostic and predictive factor in early-stage breast cancer has had mixed results. We studied p53 protein expression, by immunohistochemistry, in a randomized clinical trial of stage II patients treated with adjuvant doxorubicin and cyclophosphamide with or without paclitaxel [Cancer and Leukemia Group B (CALGB) 9344, INT0148]. Patients and Methods: Epithelial p53 expression was evaluated using two immunohistochemical antibodies (DO7 and 1801) in formalin-fixed, paraffin-embedded tissue from patients with node-positive breast cancer who were randomized to four cycles of cyclophosphamide and one of three doses of doxorubicin (60, 75, or 90 mg/m2; AC) and to receive four subsequent cycles of paclitaxel (T) or not. Prognostic and predictive value of p53 protein expression was assessed, independent of treatment assignment, for escalating doses of doxorubicin or addition of T with endpoints of relapse-free (RFS) and overall survival (OS). Results: Of 3,121 patients, 1,887 patient specimens treated on C9344 were obtained, passed quality control, and evaluated for p53 expression. Expression was 23% and 27% for mAbs 1801 and D07, respectively, with 92% concordance. In univariate analysis, p53 positivity was associated with worse OS with either antibody, but only p53 staining with monoclonal antibody 1801 had significantly worse RFS. In multivariate analysis, p53 was not predictive of RFS or OS from either doxorubicin dose escalation or addition of paclitaxel regardless of the antibody. Conclusion: Nuclear staining of p53 by immunohistochemistry is associated with worse prognosis in node-positive patients treated with adjuvant doxorubicin-based chemotherapy but is not a useful predictor of benefit from doxorubicin dose escalation or the addition of paclitaxel. Clin Cancer Res; 17(15); 5170–8. ©2011 AACR.
Decreased Perihematomal Edema in Thrombolysis-Related Intracerebral Hemorrhage Compared With Spontaneous Intracerebral Hemorrhage
Gebel, James, Brott, Thomas G. , Sila, Cathy A., Tomsick, Thomas A. , Jauch, Edward C. , Salisbury, Shelia, Miller, Rosemary, Pancioli, Arthur , Duldner, John E., Khoury, Jane , Topol, Eric J. , Broderick, Joseph P.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 31 | Issue: 3 | Pages: 596-600

10.1161/01.str.31.3.596 | PMID 10700491 Get It

Background and Purpose —Intracerebral hemorrhage (ICH) is a highly morbid disease process. Perihematomal edema is reported to contribute to clinical deterioration and death. Recent experimental observations indicate that clotting of the intrahematomal blood is the essential prerequisite for hyperacute perihematomal edema formation rather than blood-brain barrier disruption. Methods —We compared a series of patients with spontaneous ICH (SICH) to a series of patients with thrombolysis-related ICH (TICH). All patients were imaged within 3 hours of clinical onset. We reviewed relevant neuroimaging features, emphasizing and quantifying perihematomal edema. We then analyzed clinical and radiological differences between the 2 ICH types and determined whether these factors were associated with perihematomal edema. Results —TICHs contained visible perihematomal edema less than half as often as SICHs (31% versus 69%, P <0.001) and had both lower absolute edema volumes (0 cc [25th, 75th percentiles: 0, 6] versus 6 cc [0, 13], P <0.0001) and relative edema volumes (0.16 [0.10, 0.33] versus 0.55 [0.40, 0.83], P <0.0001). Compared with SICHs, TICHs were 3 times larger in volume (median [25th, 75th percentiles] volume 69 cc [30, 106] versus 21 cc [8, 45], P <0.0001), 4 times more frequently lobar in location (62% versus 15%, P <0.001), 80 times more frequently contained blood-fluid level(s) (86% versus 1%, P <0.001), and were more frequently multifocal (22% versus 0%, P <0.001). Conclusions —The striking qualitative and quantitative lack of perihematomal edema observed in the thrombolysis-related ICHs compared with the SICHs provides the first substantial, although indirect, human evidence that intrahematomal blood clotting is a plausible pathogenetic factor in hyperacute perihematomal edema formation.
Incidence rates of stroke in the eighties: the end of the decline in stroke?
Broderick, Joe, Phillips, Stephen , Whisnant, Jack P., O’Fallon, W. Michael, Bergstralh, Eric J.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 20 | Issue: 5 | Pages: 577-582

10.1161/01.str.20.5.577 | PMID 2718196 Get It

Studies of the population of Rochester, Minnesota, have provided the only data on temporal trends for the incidence of stroke in North America. Among the residents of Rochester, the average annual incidence rate of stroke declined by 46%, from 213 to 115 per 100,000 population, between 1950-1954 and 1975-1979. The decline occurred in all age and sex groups, but it occurred earlier in women than in men. The rates stabilized in the 1970s, and did so earlier in women. For 1980-1984, the incidence rate of stroke was 17% higher than that for 1975-1979. The onset of the decline in incidence rates coincided with the introduction of effective antihypertensive therapy, but stabilized and increased rates were associated with continuing improvement in the control of hypertension. The increase in the incidence rates of stroke coincided with the introduction of computed tomography, which appeared to increase the detection of less severe strokes.
Genome-Wide Linkage Analysis Reveals Evidence of Multiple Regions That Influence Variation in Plasma Lipid and Apolipoprotein Levels Associated With Risk of Coronary Heart Disease
Klos, Kathy L.E., Kardia, Sharon L.R., Ferrell, Robert E., Boerwinkle, Eric , Turner, Stephen T. , Sing, Charles F.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 17, 2011 | Volume: 21 | Issue: 6 | Pages: 971-978

10.1161/01.atv.21.6.971 | PMID 11397706 Get It

Abstract —Results of genome-wide linkage analyses to identify chromosomal regions that influence interindividual variation in plasma lipid and apolipoprotein levels in the Rochester, Minn, population are reported. Analyses were conducted for total cholesterol (total-C), triglycerides (TGs), high density lipoprotein cholesterol (HDL-C), apolipoprotein A-I, apolipoprotein A-II, apolipoprotein B, apolipoprotein C-II, apolipoprotein C-III, apolipoprotein E, the total-C/HDL-C ratio, and the TG/HDL-C ratio. Genotypes were measured for 373 genome-wide marker loci on 1484 individuals distributed among 232 multigeneration pedigrees sampled without regard to health status. LOD scores and estimates of additive genetic variance associated with map locations were obtained by using the variance-component method of linkage analysis. No evidence of linkage with genes influencing variation in age served as a negative control. Plasma apolipoprotein E levels and the apolipoprotein E gene served as a positive control (LOD score 4.20). Evidence (LOD score >2.00) was provided that was suggestive of a gene or genes on chromosomes 4 and 5 influencing variation in the apolipoprotein A-II level, on chromosome 12 influencing variation in the apolipoprotein A-I level, and on chromosome 17 influencing variation of total-C/HDL-C. These analyses provide new information about genomic regions in humans that influence interindividual variation in plasma lipid and apolipoprotein levels and serve as a basis for further fine-mapping studies to identify new genes involved in lipid metabolism.
A 15-year follow-up of neuromuscular function in patients with prior poliomyelitis
Sorenson, Eric J. , Daube, Jasper R., Windebank, Anthony J.

Mayo Clinic

Neurology | June 14, 2011 | Volume: 64 | Issue: 6 | Pages: 1070-1072

10.1212/01.wnl.0000154604.97992.4a | PMID 15781832 Get It

APOE genotype and cognitive decline in a middle-aged cohort
Blair, Cindy K. , Folsom, Aaron R. , Bray, Molly S., Boerwinkle, Eric , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Neurology | June 14, 2011 | Volume: 64 | Issue: 2 | Pages: 268-276

10.1212/01.wnl.0000149643.91367.8a | PMID 15668424 Get It